Safety of Alternative Benznidazole and Nifurtimox Regimens for Adults with Chronic Trypanosoma Cruzi Infection (TESEO): An Open-Label, Randomised, Non-Inferiority Phase 2 Trial

Cristina Alonso-VegaJimy José PintoGimena RojasWilson GarcíaAlejandro PalaciosSusana MéndezVirginia GonzalezMónica LasernaIsabela RibeiroE. Ruíz-Villamor2026-03-222026-03-22202610.2139/ssrn.6311846https://doi.org/10.2139/ssrn.6311846https://andeanlibrary.org/handle/123456789/84630BenznidazoleNifurtimoxTolerabilityMedicineDiscontinuationInternal medicineRegimenAdverse effectChagas diseaseTrypanosoma cruziSafety of Alternative Benznidazole and Nifurtimox Regimens for Adults with Chronic Trypanosoma Cruzi Infection (TESEO): An Open-Label, Randomised, Non-Inferiority Phase 2 Trialpreprint